Results 261 to 270 of about 1,458,916 (304)
Some of the next articles are maybe not open access.
Pharmacogenetics of oral anticoagulants
Pharmacogenetics, 2003There is wide interindividual variation in oral anticoagulant dose requirement, which is partly genetically determined. Several cytochrome P450s contribute to oxidative metabolism of oral anticoagulants. The most important of these is CYP2C9, which hydroxylates the S-enantiomers of warfarin, acenocoumarol and phenprocoumon with high catalytic activity.
Daly AK, King BP
openaire +3 more sources
Journal of Thrombosis and Thrombolysis, 2011
The new oral anticoagulants may prove to be one of the most significant innovations in clinical practice in the past 60Â years. Apixaban and rivaroxaban are specific inhibitors of Factor Xa while dabigatran inhibits Factor IIa. The predictable pharmacological profile of these new agents will allow physicians to use these drugs without the need for ...
Taki, Galanis +3 more
openaire +2 more sources
The new oral anticoagulants may prove to be one of the most significant innovations in clinical practice in the past 60Â years. Apixaban and rivaroxaban are specific inhibitors of Factor Xa while dabigatran inhibits Factor IIa. The predictable pharmacological profile of these new agents will allow physicians to use these drugs without the need for ...
Taki, Galanis +3 more
openaire +2 more sources
The market for oral anticoagulants
Nature Reviews Drug Discovery, 2018This article discusses the market for oral anticoagulants, and how therapies in development and antidotes to existing drugs could affect the therapeutic landscape.
Stephen, Bielecki +2 more
openaire +2 more sources
Archives of Internal Medicine, 1993
Congratulations on a good broad overview of the history and current status of oral anticoagulant drugs. 1 In this regard, I would like to mention briefly some recent data that may be of interest to readers. Kant and colleagues 2 have described the occurrence of warfarin-induced skin necrosis in relationship to peritoneal dialysis—associated loss of ...
openaire +2 more sources
Congratulations on a good broad overview of the history and current status of oral anticoagulant drugs. 1 In this regard, I would like to mention briefly some recent data that may be of interest to readers. Kant and colleagues 2 have described the occurrence of warfarin-induced skin necrosis in relationship to peritoneal dialysis—associated loss of ...
openaire +2 more sources
Trauma and oral anticoagulants
Annals of Emergency Medicine, 1983Patients on oral anticoagulants who present to the emergency department following trauma pose a special problem. Careful attention must be given to exclude any sites of overt or occult bleeding, particularly in the CNS, where there may be no external evidence of injury.
K, O'Mara, V, Mavichak
openaire +2 more sources
New England Journal of Medicine, 1991
The vitamin K-antagonist drugs were reviewed in the Journal in the early 1970s.1 , 2 Since then, there has been considerable progress in research at both a basic and an applied level. The mode of action of coumarins has been clarified; their role in the management of thromboembolic disorders has been more clearly defined; a system has been developed to
John A. Oates +2 more
openaire +2 more sources
The vitamin K-antagonist drugs were reviewed in the Journal in the early 1970s.1 , 2 Since then, there has been considerable progress in research at both a basic and an applied level. The mode of action of coumarins has been clarified; their role in the management of thromboembolic disorders has been more clearly defined; a system has been developed to
John A. Oates +2 more
openaire +2 more sources
Current Opinion in Hematology, 1996
Oral anticoagulant therapy is effective antithrombotic treatment for several indications. The results of prothrombin time monitoring should be reported as the International Normalized Ratio (INR). An INR of 2 to 3 is the recommended therapeutic range for all indications except for the prevention of systemic embolism in patients with mechanical heart ...
openaire +2 more sources
Oral anticoagulant therapy is effective antithrombotic treatment for several indications. The results of prothrombin time monitoring should be reported as the International Normalized Ratio (INR). An INR of 2 to 3 is the recommended therapeutic range for all indications except for the prevention of systemic embolism in patients with mechanical heart ...
openaire +2 more sources
The American Journal of Medicine, 2014
Warfarin has a proven record as an oral anticoagulant; almost every study, however, has found that it is not prescribed for 40-60% of patients who are eligible and should receive it, and of those who do receive it, serum warfarin levels only achieved a time in therapeutic range (TTR) equal to INR 2-3 about 55-60% of the time (online video available at:
openaire +2 more sources
Warfarin has a proven record as an oral anticoagulant; almost every study, however, has found that it is not prescribed for 40-60% of patients who are eligible and should receive it, and of those who do receive it, serum warfarin levels only achieved a time in therapeutic range (TTR) equal to INR 2-3 about 55-60% of the time (online video available at:
openaire +2 more sources
Hospital Practice, 1983
More realistic expectations regarding the efficacy of oral anticoagulants in treating thromboembolic disorders have led to more rational use of the coumarins. Their mode of action and its bearing on clinical application are discussed.
openaire +2 more sources
More realistic expectations regarding the efficacy of oral anticoagulants in treating thromboembolic disorders have led to more rational use of the coumarins. Their mode of action and its bearing on clinical application are discussed.
openaire +2 more sources